Yes, enabeler is right. The article by C.K. Jackson at Seeking Alpha was lengthy, detailed and very comprehensive. This article covers a lot of ground and should leave you with an expanded comfort-zone.
Certanly worth a read.
Not sure how you write an article about EXEL and not specifically mention GDC 0973. Seriously, a Phase 3 trial being run by Genentech/Roche, in a significant indication. If the drug works as well in the Phase 3 as it did in the BRIM7 phase 1b dose escalation study, it may well be worth $1.5-2B in market valuation by itself. Seeking Alpha should be Seeking more informed contributors.
"There is reason for investors and prostate cancer patients to have high hopes for cabozintanib.
On December 4, 2012, University of Michigan Comprehensive Cancer Center announced results that found Cometriq demonstrated rapid effects on prostate cancer that had metastasized to bone.
The study was comprised of 171 men with prostate cancer whose tumors no longer responded to hormone-based therapies. All of the patients were treated with cabozintanib for 12 weeks. At that point, they were randomly assigned to receive continued cabozantinib or placebo. The randomization was stopped early, however, because of the beneficial effects of cabozintanib seen on bone scans, and because patients receiving placebo progressed more quickly than did those that remained on the study drug."